According to recently published report by Future Market Insights, the global atopic dermatitis treatment market size is expected to reach US$ 26 Bn by 2029.
According to recently published report by Future Market Insights (FMI), the global atopic dermatitis treatment market size is expected to reach US$ 26 Bn by 2029. Atopic dermatitis is a widespread chronic inflammatory skin disease that affects patients of all ages, especially children, resulting from a complex interplay of immunological, environmental, pharmacologic, and genetic factors. Higher treatment compliances, promising pipeline molecules, increasing prevalence, growing access to treatment medication in developing countries, and advancing technologies are some of the major factors that are expected to boost the market growth.
Researchers and scientists are constantly working towards the development of medication to cure atopic dermatitis permanently. In order to ensure permanent cure, Eli Lilly and Company and Incyte declared rheumatoid arthritis (RA) drug Olumiant (baricitinib) for treating the disease. The company evaluated RA drug olumiant and showed that these drugs are safe and efficient for treatment of adults with moderate to severe atopic dermatitis. Furthermore, a study conducted at Tel Aviv University study found the precise receptor chain involved in the development of atopic dermatitis. Researchers are focusing on developing an antibody to create a therapeutic drug, which will help in curing atopic dermatitis along with other allergic diseases such as asthma or eosinophilic esophagitis.
For more insights into the Market, request a sample of this report@
https://www.futuremarketinsights.com/reports/sample/rep-gb-3097
Corticosteroids Remain the Most Preferred Drug
For pain and inflammation relief, corticosteroids inhibitors remain the drug of choice in atopic dermatitis treatment space. This drug mediates anti-inflammatory effects in affected cells that can lead to a few side effects, particularly in pediatric patients, such as swelling, itching, redness, and allergy. Additionally, corticosteroids are used as the first line of treatment for different diseases such as severe allergies, asthma, and arthritis. Owing to this, corticosteroids will continue to witness higher demand until the first half of the forecast period, while adoption of emollients is expected to pick pace and overtake corticosteroids by 2023. Furthermore, demand for PDE-4 inhibitor is projected to grow at highly remarkable CAGR of 26% over the forecast period. Currently, PDE-4 inhibitor has been developed to target the inflammatory cascade of atopic dermatitis in both topical and oral formulation.
Dermatology Clinics Emerge as Major Distribution Channel
Atopic dermatitis treatment in dermatology clinics will continue to account for a relatively high revenue share. The demand from dermatology clinics is poised to grow at noticeable CAGR of 18% during the forecast period 2019-2029. Further, distribution of medications for atopic dermatitis treatment via hospital pharmacies is expected to generate a revenue of US$ 6.2 Bn by 2029, owing to easy and faster access to medications as per scheduled prescription.
Request special price for this report to our sales executive@
https://www.futuremarketinsights.com/request-special-price/rep-gb-3097
“Growth prospects of the atopic dermatitis market are high in North America, due to early adoption of novel prescriptions, increasing business associations of pharmaceutical organizations with contract research organizations in developing markets, better and favorable reimbursement policies, advanced healthcare infrastructure, and greater treatment awareness among the patient population across the United States and Canada,” says FMI analyst.
About Us
Future Market Insights (FMI) is a leading market intelligence and consulting firm. We deliver syndicated research reports, custom research reports and consulting services which are personalized in nature. FMI delivers a complete packaged solution, which combines current market intelligence, statistical anecdotes, technology inputs, valuable growth insights and an aerial view of the competitive framework and future market trends.
Contact Us
Mr. Abhishek Budholiya
616 Corporate Way, Suite 2-9018,
Valley Cottage, NY 10989,
United States
T: +1-347-918-3531
F: +1-845-579-5705
T (UK): + 44 (0) 20 7692 8790
Sales: sales@futuremarketinsights.com
Press Office: Press@futuremarketinsights.com
Website: https:www.futuremarketinsights.com
